Sancti Spiritus, Cuba, Mar 6 (Prensa Latina) The 3rd phase of clinical trials to evaluate the efficacy and safety of the NeuralCIM neuroprotective drug in patients with mild or moderate Alzheimer's amnesic variant is being carried out in this central Cuban province, medical specialists reported on Monday.